Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Edmundo Stahl"'
Autor:
Pinkus Goldberg, Paul Chervinsky, Stanley P. Galant, Teresa Arledge, Yonghua Wang, Mary Beth Welch, Edmundo Stahl
Publikováno v:
Chest. 115:642-648
Study objectives This study investigates the long-term cardiovascular safety of salmeterol powder vs placebo in adolescent and adult patients with mild persistent asthma. Design Multicenter, randomized, double-blind, placebo-controlled, parallel-grou
Autor:
Yonghua Wang, Teresa Arledge, Edmundo Stahl, David S. Pearlman, Catherine Scott, Kathryn V. Blake
Publikováno v:
Annals of Allergy, Asthma & Immunology. 82:205-211
Exercise-induced bronchospasm (EIB) is a common problem in children with asthma. Pretreatment with the beta2 (beta 2)-adrenoreceptor agonist albuterol is effective for preventing EIB, but is recognized as providing only short-term (2 to 3 hour) prote
Autor:
Steven F. Weinstein, Austin Byrne, Edwin A. Bronsky, Terri Arledge, Edmundo Stahl, David S. Pearlman, Roger Liddle
Publikováno v:
Annals of Allergy, Asthma & Immunology. 81:51-58
The efficacy and safety of salmeterol powder have not previously been evaluated in children with asthma in the United States.The efficacy and safety of salmeterol powder versus placebo were compared in children between the ages of 4 and 11 years with
Autor:
Edmundo Stahl, James Wolfe, Roger Liddle, Craig LaForce, James Grady, Teresa Arledge, James P. Kemp
Publikováno v:
Clinical Therapeutics. 20:270-282
Two multicenter, randomized, double-masked, placebo-controlled studies involving 451 adolescent and adult patients with mild-to-moderate asthma compared the efficacy and safety of salmeterol powder 50 micrograms twice daily with albuterol 180 microgr
Autor:
Steven F. Weinstein, Edmundo Stahl, Edwin A. Bronsky, Roger Liddle, Robert A. Nathan, William C. Howland, Stephen J. Pollard, Bruce M. Prenner, Paul Chervinsky
Publikováno v:
Journal of Asthma. 34:43-52
This was a 1-week study evaluating the safety and efficacy of two dosage regimens of salmeterol in children with asthma. A total of 243 children, aged 4-11 years, with mild-to-moderate asthma were enrolled in a randomized, double-blind, placebo-contr
Autor:
Edmundo Stahl
Publikováno v:
Modern Approaches To Quality Control
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b27f4c97092465b7889dcd35b88acc3
https://doi.org/10.5772/24309
https://doi.org/10.5772/24309
Autor:
Tracy T. Survill, Edmundo Stahl, P. E. Mortensen, Per Cantor, Ida Gjorup, John Myhre, Helge Worning
Publikováno v:
Gastroenterology. 102:1742-1751
To determine the physiological role of circulating cholecystokinin (CCK), the effect of the CCK receptor antagonist MK-329 on upper digestive processes was investigated in six normal volunteers after a mixed meal. In a double-blind, two-period, rando
Autor:
James Wolfe, Stephen Kreitzer, Paul Chervinsky, Suzanne Davis, Donna Reilly, Yonghua Wang, Michael S. Lawrence, Edmundo Stahl
Publikováno v:
Annals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology. 84(3)
Background The efficacy and safety of the aerosol metered-dose inhaler (MDI) formulation of salmeterol for asthma symptoms have been established. Recently, salmeterol has been introduced as a micronized powder formulation administered via a breath-ac
Autor:
David S. Pearlman, Teresa Arledge, Edmundo Stahl, Mary Beth Welch, Thomas G. O’Riordan, Yonghua Wang, James P. Kemp, Arthur C. DeGraff, Myra Rosario Herrle
Publikováno v:
The Journal of allergy and clinical immunology. 104(6)
Background: Long-acting β 2 -sympathomimetic agonists such as salmeterol have been proved safe and effective for the treatment of asthma. However, controversy still exists as to the appropriateness of scheduled long-term therapy with these agents. O
Autor:
Edwin A. Bronsky, Edmundo Stahl, Yonghua Wang, Catherine Scott, Bonnie F Pobiner, David S. Pearlman
Publikováno v:
Pediatrics. 104(3 Pt 1)
Background. A powder formulation of salmeterol has been shown to prevent exercise-induced bronchospasm (EIB) in asthmatic children and adults; however, the delivery device (Diskhaler; Glaxo Wellcome Inc, Research Triangle Park, NC) must be reloaded a